Date: 2015-02-23
Type of information: R&D agreement
Compound:
Company: Foundation Medicine (USA -MA) H3 Biomedicine (USA -MA)
Therapeutic area: Cancer - Oncology
Type agreement: R&D
Action mechanism:
Disease:
Details: * On February 23, 2015, Foundation Medicine and H3 Biomedicine announced a multi-year collaboration for the discovery and development of precision medicines in oncology. The collaboration marries Foundation Medicine\'s comprehensive genomic knowledgebase of more than 35,000 genomic profiles, FoundationCORE™, with H3 Biomedicine\'s drug discovery engine and computational biology platform. The approach aims to identify potential drug targets based on the unique genomic dependencies of individual cancers, rapidly accelerate clinical development, and lead to the commercialization of new, safe and effective precision medicines for individuals living with cancer.
Under the terms of the agreement, H3 Biomedicine will pay Foundation Medicine a technology access fee for identification of target concepts arising from FoundationCORE and success milestones for selection, validation, clinical progression, and commercialization of products developed from the program. In addition, Foundation Medicine is eligible to receive royalties on sales of any products resulting from the collaboration.
Financial terms:
Latest news:
